The activist group's stake remains static at 38.9M shares, but their influence is diluted by the new issuance. Watch for any subsequent 13D amendments that signal a change in strategy, such as new demands or a sale of shares, as the group may reassess its position given the reduced ownership percentage.
Price Chart
Executive Summary
Sino Lion Ventures Ltd and Chenhao Xu filed Amendment No. 3 to their Schedule 13D, reporting a decrease in beneficial ownership from approximately 29.2% to 25.325% of Indaptus Therapeutics' common stock. The decrease was solely due to the issuance of 20,338,974 new shares in a private placement on October 16, 2026, not from any sale by the Reporting Persons. The Reporting Persons continue to hold 38,895,000 shares unchanged, but their percentage dropped because the total share count increased to 153,581,298. This is a passive dilution event with no change in intent or demands.
Key Financial Metrics
Key Facts
- Sino Lion Ventures Ltd and Chenhao Xu beneficially own 38,895,000 shares of Indaptus common stock, unchanged from prior filing.
- Ownership percentage decreased from ~29.2% to 25.325% due to the issuance of 20,338,974 new shares in a private placement that closed on October 16, 2026.
- The Reporting Persons did not acquire or dispose of any shares in connection with this filing.
- The stake was originally acquired via conversion of Series AA and Series AAA Preferred Stock purchased on March 23, 2026 for $3,998,898.44.
- No new demands, intentions, or changes to the stated purpose were reported.
Financial Impact
Passive dilution of the Reporting Persons' stake from ~29.2% to 25.325% due to a 20,338,974-share private placement. No cash impact on the Reporting Persons.
Risk Factors
- Further dilution from additional equity issuances could continue to reduce the activist group's influence.
- The company's ongoing evaluation of a strategic transaction (Post-Investment Transaction) may alter the activist's calculus.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D/A Filing (Primary) | 0001829126-26-011445 |
| Document: 0001829126-26-011445-index.html | 0001829126-26-011445 |
| Document: 0001829126-26-011445.txt | 0001829126-26-011445 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.35 (+5.85%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.35 (+5.85%) |
Oct 22, 2026 4d ago | SC 13D/A | $3.16 | awaiting T+60 | — | $3.35 (+5.85%) |
Oct 21, 2026 5d ago | SC 13D/A | $2.99 | awaiting T+60 | — | $3.35 (+11.87%) |
Oct 20, 2026 6d ago | 8-K | $3.16 | awaiting T+60 | — | $3.35 (−5.85%) |
Sep 30, 2026 27d ago | 8-K | $2.30 | awaiting T+60 | — | $3.35 (+45.43%) |
Sep 9, 2026 6w ago | 8-K | $2.56 | awaiting T+60 | — | $3.35 (−30.66%) |
Sep 4, 2026 7w ago | 424B5 | $1.85 | awaiting T+60 | — | $3.35 (−80.81%) |
Sep 1, 2026 8w ago | 8-K | $1.13 | awaiting T+60 | — | $3.35 (−196.02%) |
Aug 26, 2026 8w ago | EFFECT | $1.14 | awaiting T+60 | — | $3.35 (−193.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers